Literature DB >> 15483472

Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women.

Lorna E Thorpe1, Margaret Frederick, Jane Pitt, Irene Cheng, D Heather Watts, Shelley Buschur, Karen Green, Carmen Zorrilla, Sheldon H Landesman, Ronald C Hershow.   

Abstract

In vitro and animal studies suggest that cocaine and heroin increase HIV replication and suppress immune function, whereas epidemiologic studies are inconclusive regarding their effect on HIV infection progression. The authors prospectively examined the association between illicit-drug use and 4 outcome measures (CD4 cell percentage, HIV RNA level, survival to class C diagnosis of HIV infection, and death) in a national cohort of HIV-infected women. Women enrolled between 1989 and 1995 were followed for 5 years and repeatedly interviewed about illicit ("hard")--drug use. Up to 3 periodic urine screens validated self-reported use. Outcomes were compared between hard-drug users (women using cocaine, heroin, methadone, or injecting drugs) and nonusers, adjusting for age, antiretroviral therapy, number of pregnancies, smoking, and baseline CD4 cell percentage. Of 1148 women, 40% reported baseline hard-drug use during pregnancy. In multivariate analyses, hard-drug use was not associated with change in CD4 cell percentage (P = 0.84), HIV RNA level (P = 0.48), or all-cause mortality (relative hazard = 1.10; 95% confidence interval, 0.61-1.98). Hard-drug users did, however, exhibit a higher risk of developing class C diagnoses (relative hazard = 1.65; 95% confidence interval, 1.00-2.72), especially herpes, pulmonary tuberculosis, and recurrent pneumonia. Hard-drug-using women may have a higher risk for nonfatal opportunistic infections.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15483472     DOI: 10.1097/01.qai.0000127354.78706.5d

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  24 in total

1.  Improving survival among HIV-infected injection drug users: how should we define success?

Authors:  Gregory D Kirk; David Vlahov
Journal:  Clin Infect Dis       Date:  2007-06-19       Impact factor: 9.079

2.  Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances.

Authors:  Randi Melissa Schuster; Raul Gonzalez
Journal:  Neurobehav HIV Med       Date:  2012-02-16

3.  Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.

Authors:  Farah Ladak; Eugenia Socias; Seonaid Nolan; Huiru Dong; Thomas Kerr; Evan Wood; Julio Montaner; M-J Milloy
Journal:  Antivir Ther       Date:  2019

4.  Excess mortality among HIV-infected patients diagnosed with substance use dependence or abuse receiving care in a fully integrated medical care program.

Authors:  Gerald N DeLorenze; Constance Weisner; Ai-Lin Tsai; Derek D Satre; Charles P Quesenberry
Journal:  Alcohol Clin Exp Res       Date:  2010-11-08       Impact factor: 3.455

5.  The relationship between injection and noninjection drug use and HIV disease progression.

Authors:  Han-Zhu Qian; Samuel E Stinnette; Peter F Rebeiro; Aaron M Kipp; Bryan E Shepherd; Charles P Samenow; Cathy A Jenkins; Paul No; Catherine C McGowan; Todd Hulgan; Timothy R Sterling
Journal:  J Subst Abuse Treat       Date:  2011-02-23

6.  Assessing the effects of drug misuse on HIV/AIDS prevalence.

Authors:  C P Bhunu; S Mushayabasa
Journal:  Theory Biosci       Date:  2012-12-06       Impact factor: 1.919

7.  Rhesus macaque model of chronic opiate dependence and neuro-AIDS: longitudinal assessment of auditory brainstem responses and visual evoked potentials.

Authors:  Mariam Riazi; Joanne K Marcario; Frank K Samson; Himanshu Kenjale; Istvan Adany; Vincent Staggs; Emily Ledford; Janet Marquis; Opendra Narayan; Paul D Cheney
Journal:  J Neuroimmune Pharmacol       Date:  2009-03-13       Impact factor: 4.147

8.  Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women.

Authors:  Judith A Cook; Jane K Burke-Miller; Mardge H Cohen; Robert L Cook; David Vlahov; Tracey E Wilson; Elizabeth T Golub; Rebecca M Schwartz; Andrea A Howard; Claudia Ponath; Michael W Plankey; Alexandra M Levine; Andrea Levine; Dennis D Grey
Journal:  AIDS       Date:  2008-07-11       Impact factor: 4.177

9.  HIV disease progression to CD4 count <200 cells/μL and death in Saskatoon, Saskatchewan.

Authors:  Stephanie Konrad; Stuart Skinner; Germain Bukassa Kazadi; Kali Gartner; Hyun June Lim
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

10.  The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy.

Authors:  E J Edelman; K S Gordon; J P Tate; W C Becker; K Bryant; K Crothers; J R Gaither; C L Gibert; A J Gordon; Bdl Marshall; M C Rodriguez-Barradas; J H Samet; M Skanderson; A C Justice; D A Fiellin
Journal:  HIV Med       Date:  2016-11       Impact factor: 3.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.